Survey Says... - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Survey Says...
New data provide insight into pharma-industry professionals' daily lives.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 12


Michelle Hoffman
You've probably been getting a lot of requests to fill out surveys lately, including requests from us (but more on that later). You do know why, don't you? These are the months that journals set their editorial calendars, that trade-show organizers craft their programs, and that vendors design their advertising campaigns. They all want to know about you. The only people who probably don't get to know about your interests and careers are, well, you. So, I'll fill you in.

Recently, we obtained results from an independent survey of industry professionals who belong to some of the professional organizations and attend the large industry trade shows. The survey, conducted in July, was sent out to 34,247 people, 353 of which completed the entire survey. The following results reflect their responses.


Figure 1
More than half (53%) of the respondents come from conventional bio/pharmaceutical manufacturing companies. An additional 13% are consultants; 10.4% perform research and/or analytical services; 9.3% are in drug-delivery technology manufacturing; 5.4% work with ingredients, excipients, active pharmaceutical ingredients, and/or specialty chemicals; and the remainder are in education, government, architecture, engineering, or construction (see Figure 1). Twenty-one percent describe their job function as scientist, 20% as manager, 18% as director, and 13% as CEO or vice-president.

Twenty-seven percent are engaged in research and development (R&D), 22% in quality control/assurance or validation, 11% in technical or analytical services and support, 9% in marketing sales and management, 8% in production and manufacturing, and 6.5% are engaged in project management. The remaining respondents fall into engineering (5.4%), corporate management (4.3%), education, regulatory affairs, materials management/purchasing/procurement, and packaging.

On average, your companies earn revenues of $10 billion a year and spend $196 million on R&D. Thirty-six percent of you report that your companies are planning to expand and/or build new facilities in the coming year, and 48% of those say that expansions are planned in the United States; 19% say Western Europe, 8% say China; and 3% say India. Forty-three percent of respondents report that their company plans to sell products into the BRIC (Brazil, Russia, India, and China) countries, and 35% say their companies plan to source materials from BRIC countries.

Of the 73% of you that are interested in receiving additional professional training, 37% are interested in learning more about topics related to quality assurance and control. Approximately the same percentage of respondents want to learn more about regulatory affairs. Thirty-four percent are interested in validation, and the same percentage want to increase their knowledge of process development.

This particular survey did not ask about your sex, but anyone who's attended a conference or trade show in this industry knows that it's overwhelmingly male. Other surveys indicate that about 75–80% of bio/pharmaceutical industry employees are male.

As for what you like to read and how, we are collecting those data now through the PharmTech reader-assessment survey. To get you the information you need when and how you need it, please take some time to fill us in. You can access the survey online at http://www.surveymonkey.com/s/QFC7VFT. We look forward to learning even more about you.

Michelle Hoffman is editor-in-chief of Pharmaceutical Technology. Send your thoughts and story ideas to

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here